Purpose: Evidence regarding red blood cell (RBC) transfusion practices and their impact on hematopoietic cell transplantation (HCT) outcomes are poorly understood.

Patients And Methods: We performed a noninferiority randomized controlled trial in four different centers that evaluated patients with hematologic malignancies requiring HCT who were randomly assigned to either a restrictive (hemoglobin [Hb] threshold < 70 g/L) or liberal (Hb threshold < 90 g/L) RBC transfusion strategy between day 0 and day 100. The noninferiority margin corresponds to a 12% absolute difference between groups in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) score relative to baseline. The primary outcome was health-related quality of life (HRQOL) measured by FACT-BMT score at day 100. Additional end points were collected: HRQOL by FACT-BMT score at baseline and at days 7, 14, 28, 60, and 100; transplantation-related mortality; length of hospital stay; intensive care unit admissions; acute graft-versus-host disease; Bearman toxicity score; sinusoidal obstruction syndrome; serious infections; WHO Bleeding Scale; transfusion requirements; and reactions to therapy.

Results: A total of 300 patients were randomly assigned to either restrictive-strategy or liberal-strategy treatment groups between 2011 and 2016 at four Canadian adult HCT centers. After HCT, mean pre-transfusion Hb levels were 70.9 g/L in the restrictive-strategy group and 84.6 g/L in the liberal-strategy group ( < .0001). The number of RBC units transfused was lower in the restrictive-strategy group than in the liberal-strategy group (mean, 2.73 units [standard deviation, 4.81 units] 5.02 units [standard deviation, 6.13 units]; = .0004). After adjusting for transfusion type and baseline FACT-BMT score, the restrictive-strategy group had a higher FACT-BMT score at day 100 (difference of 1.6 points; 95% CI, -2.5 to 5.6 points), which was noninferior compared with that of the liberal-strategy group. There were no significant differences in clinical outcomes between the transfusion strategies.

Conclusion: In patients undergoing HCT, the use of a restrictive RBC transfusion strategy threshold of 70 g/L was as effective as a threshold of 90 g/L and resulted in similar HRQOL and HCT outcomes with fewer transfusions.

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01836DOI Listing

Publication Analysis

Top Keywords

fact-bmt score
20
threshold g/l
16
rbc transfusion
12
day 100
12
restrictive-strategy group
12
liberal-strategy group
12
red blood
8
blood cell
8
hematopoietic cell
8
cell transplantation
8

Similar Publications

Importance: Although sharing care with local oncologists after allogeneic hematopoietic cell transplantation (HCT) has been proposed for patients living far from HCT centers, it is not known whether a shared strategy is safe or improves patient quality of life (QOL).

Objective: To determine the efficacy and safety of sharing follow-up care after HCT between the HCT specialty center and local oncologists.

Design, Setting, And Participants: This was a multicenter collaborative randomized clinical trial of patients undergoing HCT at Dana-Farber Cancer Institute (DFCI)-a high volume HCT center in Boston (Massachusetts)-and 8 local oncology practices.

View Article and Find Full Text PDF
Article Synopsis
  • The BMT Clinical Trials Network conducted a phase 3 trial comparing gilteritinib to a placebo in patients with FLT3-ITD+ acute myeloid leukemia (AML) after hematopoietic cell transplantation (HCT).
  • The study found no significant difference in relapse-free survival or health-related quality of life (HRQOL) between the two groups, despite more treatment-related side effects in those taking gilteritinib.
  • Overall, gilteritinib maintenance did not lead to improved HRQOL, and results were consistent across different patient subgroups in terms of measurable residual disease.
View Article and Find Full Text PDF

Introduction: This prospective multicentre study evaluates the impact of Palliative Care Unit (PCU) intervention (Experimental Group, EG), during autologous hematopoietic stem cell transplantation (AHSCT) on quality of life (QoL), symptom control and healthcare resource use compared to standard practice (Control Group, CG). We used validated scales on Days 0 (stem cell infusion), + 7 (bone marrow aplasia, acute symptoms) and + 21 (aplasia recovery).

Results: In 40 patients (20 EG/ 20 CG: 45%/25% female, median age 57.

View Article and Find Full Text PDF
Article Synopsis
  • The European Stroke Organisation (ESO) developed guidelines for managing basilar artery occlusion (BAO) due to its poor outcomes, despite being a small percentage of strokes.
  • The guidelines were created using the GRADE methodology and involved a systematic literature review based on 10 clinical questions identified as critical (PICO).
  • The findings suggest using intravenous thrombolysis (IVT) within 24 hours for BAO patients, combined with endovascular treatments for better outcomes, but results varied depending on factors like treatment location and initial stroke severity.
View Article and Find Full Text PDF

Aim: This study aimed to explore the association between patient-reported items at different time points after hematopoietic stem cell transplantation (HSCT) and long-term survival.

Methods: We conducted a study with 144 allogeneic HSCT patients, following them for 5 years post-transplantation. Data from the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) questionnaire were collected before transplantation and at 1, 3, 6, 12, 18, 36, and 60 months after transplantation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!